Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Status Post Lung Transplant Clear all
Recruiting Phase 2 Interventional

Xenon MRI Pulm Hypertension

NCT04991454
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00058292
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Phase 3 Interventional

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

NCT00755781
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Hyperbaric Oxygen Therapy for Lung Transplantation

NCT02363959
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Central Airway Stenosis, Airway Exudative Plaques, Airway Complications Post-Lung Transplantation
Interventions
Hyperbaric Oxygen Therapy, Endobronchial Biopsy of Airway Epithelium
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 5, 2026, 5:41 AM EDT
Completed No phase listed Observational

Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation

NCT03299504
View directory record Official record
Conditions
Lung Transplant
Interventions
Exercise
Other
Lead sponsor
Indiana University Health Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Early Phase 1 Interventional

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

NCT04521569
View directory record Official record
Conditions
Lung Transplant
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 5, 2026, 5:41 AM EDT
Withdrawn Not applicable Interventional

The Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation

NCT00783679
View directory record Official record
Conditions
Cardiac Physiology, Cardiac Output
Interventions
NICO device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 5, 2026, 5:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

NCT04941573
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 5, 2026, 5:41 AM EDT
Enrolling by invitation Early Phase 1 Interventional

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

NCT05950724
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Etanercept Injection [Enbrel]
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation

NCT01694563
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Interventions
Synergy Ablation System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
49
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 5, 2026, 5:41 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

NCT01852370
View directory record Official record
Conditions
Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease, Common Variable Immune Deficiency (CVID)
Interventions
CD3/CD19 negative allogeneic hematopoietic stem cells
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

NCT01469364
View directory record Official record
Conditions
Complication of Transplanted Lung
Interventions
Aztreonam Lysine for Inhalation (AZLI), Status Post Lung Transplant
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 5, 2026, 5:41 AM EDT
Active, not recruiting No phase listed Observational

Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation

NCT00457847
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 65 Years
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Not listed No phase listed Observational

Impact of Atelectasis on RVEDP Following Orthotropic Heart Transplantation

NCT06140810
View directory record Official record
Conditions
Heart Transplant Failure, Anesthesia
Interventions
Lung Recruitment
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 5, 2026, 5:41 AM EDT
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Completed No phase listed Observational

OCS Lung Expand Post-Approval Study - Expand Follow-Up Data Collection

NCT04194398
View directory record Official record
Conditions
OCS Lung System
Interventions
OCS Lung System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Timeline
2018 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

NCT00227370
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 5, 2026, 5:41 AM EDT
Completed No phase listed Observational Results available

A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation

NCT06503770
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Not listed
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cleveland, Ohio • Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

NCT05907746
View directory record Official record
Conditions
GATA2, Immunodeficiency
Interventions
Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide, Total Body Irradiation, Hematopoietic Cell Transplant, Briquilimab, Cyclophosphamide, Fludarabine, Bone Marrow Biopsy, Bone Marrow Aspirate, 2D echo, EKG, PFT's, CT scan of chest, abdomen and pelvis
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Completed No phase listed Observational

Imaging and Understanding BOS in Lung Transplantation

NCT02316392
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Hyperpolarized Helium-3 MRI
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 5, 2026, 5:41 AM EDT
Active, not recruiting Phase 2 Interventional

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957
View directory record Official record
Conditions
Cytomegalovirus Infections, Transplant-Related Disorder
Interventions
Letermovir 480 MG [Prevymis]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass

NCT00032630
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Coronary artery bypass - on-pump, Coronary artery bypass - off-pump
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
2,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Palo Alto, California • San Francisco, California • Sepulveda, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 5, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Improving Lung Transplant Outcomes With Coping Skills and Physical Activity

NCT04093869
View directory record Official record
Conditions
Post-Lung Transplantation
Interventions
Coping Skills Training combined with Exercise (CSTEX), Standard of Care plus Education (SOC-ED)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 5, 2026, 5:41 AM EDT
Terminated Phase 1 Interventional

Cardiac Allograft Remodeling and Effects of Sirolimus

NCT01889992
View directory record Official record
Conditions
Cardiac Hypertrophy, Immunosuppression
Interventions
Cardiac MRI, Coronary angiography with IVUS, Cardiac Allograft Remodeling, M-TOR Immunosuppression, Cardiac Biopsy C4D stain, Genetic Mechanism of M-TOR, Cardiopulmonary Exercise Test (CPET)
Radiation · Procedure · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 5, 2026, 5:41 AM EDT